Quality doesn't always come cheap on the ASX. However, when strong ASX shares fall out of favour, opportunity can open up.
REA Group Ltd (ASX: REA), Pro Medicus Ltd (ASX: PME) and GQG Partners Inc. (ASX: GQG) are three high-profile names on the ASX that have seen their share prices retreat 20% or even 40% in the past 6 months. This despite retaining long-term growth drivers.
For investors willing to look past short-term volatility, these beaten-down ASX shares could offer attractive upside from current levels.
Image source: Getty Images
REA Group Ltd (ASX: REA)
REA Group shares have cooled significantly after a strong run over recent years. The ASX share pulled back sharply 21% in the past 6 months to $189.75 at the time of writing.
The fall of the blue chip share was a result of higher interest rates and softer housing activity that weighed on listing volumes and sentiment.
Despite that, REA's underlying business remains one of the strongest digital marketplaces on the ASX. Realestate.com.au dominates Australian property listings, giving the company pricing power and resilient margins.
Revenue growth can slow when property markets cool, and regulatory scrutiny remains a risk, but history shows activity eventually rebounds. If housing turnover stabilises, REA's earnings leverage could drive a renewed re-rating.
Most brokers see the ASX 200 share as a buy, with an average 12-month price target of $235.05. That points to a 45% upside.
Pro Medicus Ltd (ASX: PME)
This ASX healthcare share has also experienced a meaningful pullback after years of exceptional gains. The company's share price surged as its medical imaging software won major hospital contracts globally, but valuation concerns and broader growth stock sell-offs have taken some heat out of the rally.
The ASX 200 share lost 42% of its value in the past 6 months and currently trades at $184.12 apiece. No wonder most analysts see serious upside ahead. The consensus price target for the ASX share is set at $296.19, a potential gain of 61% for the next 12 months.
Brokers think that Pro Medicus' long-term story remains compelling. The ASX share operates a high-margin, capital-light business with sticky customers and recurring revenue.
The main risk lies in its premium valuation and reliance on hospital spending cycles, which can delay contract decisions. Even so, continued global rollout of its technology supports the case that recent weakness may represent an entry point rather than a warning sign.
GQG Partners Inc. (ASX: GQG)
GQG Partners rounds out the trio as a very different kind of opportunity. The price of the ASX share has drifted 23% lower over 6 months amid market volatility and periods of investor outflows.
As an active manager, GQG's earnings are tied to assets under management, which can fall quickly when performance lags benchmarks. That said, the business still generates strong cash flows, operates with a low-cost structure and pays a generous dividend.
If markets improve and performance stabilises, sentiment could turn quickly. Market watchers rate the current valuation of $1.57 as overly pessimistic. They think the ASX share could climb to $2.06 in the next 12 months, a potential upside of 31%.
